Prevalence of gastrointestinal stromal tumour (GIST) in the United Kingdom at different therapeutic lines: an epidemiologic model

BACKGROUND: The prevalence of patients with gastrointestinal stromal tumourgst (GIST) who fail currently available treatments imatinib and sunitinib (third-line treatment-eligible GIST) is unknown, but is expected to be below an ultra-orphan disease threshold of 2/100,000 population used in England...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Starczewska Amelio, Justyna M, Cid Ruzafa, Javier, Desai, Kamal, Tzivelekis, Spiros, Muston, Dominic, Khalid, Javaria Mona, Ashman, Philip, Maguire, Andrew
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2014
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4039646/
https://ncbi.nlm.nih.gov/pubmed/24884940
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-364
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados